Press Releases

Investor Alerts

Feb 18, 2020

Satsuma Pharmaceuticals to Present at the 9th Annual SVB Leerink Global Healthcare Conference
Jan 28, 2020

Satsuma Pharmaceuticals Announces Publication of STS101 Phase 1 Clinical Trial Results in HEADACHE: The Journal of Head and Face Pain
Nov 26, 2019

Satsuma Pharmaceuticals to Present at the 2nd Annual Evercore ISI HealthCONx Conference
Nov 12, 2019

Satsuma Pharmaceuticals Reports Third Quarter 2019 Financial and Business Results

Completed upsized initial public offering of $90.8 million in gross proceeds
Sep 17, 2019

Satsuma Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
Sep 12, 2019

Satsuma Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering of Common Stock
Sep 3, 2019

Satsuma Pharmaceuticals Announces Poster Presentations at the International Headache Congress
Sep 3, 2019

Satsuma Pharmaceuticals, Inc. Announces Proposed Initial Public Offering of Common Stock
Aug 22, 2019

Satsuma Pharmaceuticals Announces First Patient Dosed in EMERGE™, a Phase 3 Efficacy Trial of STS101 for the Acute Treatment of Migraine
Jul 8, 2019

Satsuma Pharmaceuticals Announces Presentation of STS101 (Dihydroergotamine Nasal Powder) Phase 1 Trial Results at American Headache Society's Annual Scientific Meeting

-- Favorable Pharmacokinetic, Safety, and Tolerability Results Support Advancing STS101 into Pivotal Phase 3 Efficacy Trial

Show per page